The Asthma Landscape in the UK
The UK carries one of the heaviest asthma burdens in Europe. Around 5.4 million people receive treatment for the condition, including roughly 1.1 million children and 4.3 million adults. Every day, approximately 185 people attend hospital because of an asthma attack. Lung disease remains the third leading cause of death in the UK, yet Asthma + Lung UK has pointed out that research funding for respiratory conditions has not kept pace with the scale of the problem. This makes clinical trials more than just scientific exercises — they are a necessary part of closing the gap between what treatments exist and what patients actually need.
For people like Tom, a 47-year-old teacher from Manchester, the frustration is familiar. He spent years cycling through different combination inhalers, never quite reaching the control he hoped for. His consultant eventually mentioned a trial testing a new biologic, and that conversation shifted his outlook. Stories like Tom's are common. People simply do not hear about research opportunities until they stumble upon them by chance, often through a well-informed specialist or a charity leaflet in a waiting room.
The geography of asthma trials in the UK matters too. Major research hubs exist in London, Oxford, Birmingham, Manchester, Edinburgh, and Leicester, but smaller centres and GP surgeries are increasingly involved — particularly in studies like IMP2ART, which is testing ways to embed improved asthma self-management into routine primary care across the UK. If you live outside a major city, you may still find a trial within reach.
Recent Breakthroughs Emerging from UK Research
Several significant trials have recently put UK asthma research in the spotlight. The ABRA trial, conducted at Oxford University Hospitals NHS Foundation Trust and Guy's and St Thomas' NHS Foundation Trust, investigated benralizumab — a monoclonal antibody that targets eosinophils, the cells driving inflammation in many asthma patients — as an emergency treatment during attacks. The findings suggested that a single injection given at the point of an exacerbation could be more effective than the standard five-day course of prednisolone tablets. Described by some researchers as the first new treatment for asthma attacks in fifty years, the ABRA trial was designed and delivered entirely within the NHS.
Another notable development is the Wayfinder trial, which examined tezepelumab (marketed as Tezspire), a drug developed by AstraZeneca. Results indicated that a once-monthly injection could help patients with severe asthma reduce or even stop daily oral steroid use. For those who have relied on prednisolone for years — facing side effects such as bone density loss, weight gain, and heightened infection risk — this represents a meaningful shift in what long-term management can look like. Professor David Jackson of King's College London, who led the research, noted that the drug's effects extended beyond asthma symptoms to improvements in related conditions like chronic rhinosinusitis.
The paediatric space is advancing too. The TREAT trial is comparing mepolizumab with omalizumab in children with severe asthma, addressing a group where treatment options have historically been limited and where parents are understandably cautious about long-term medication effects. Meanwhile, a phase 2 study of rilzabrutinib, published in The Lancet Respiratory Medicine, explored a new class of oral medication for adults with moderate-to-severe uncontrolled asthma — suggesting that the pipeline of potential therapies remains active.
These trials share a common thread: they investigate whether targeted therapies can replace or reduce reliance on broad-spectrum steroids, which have been the default rescue option for decades.
Types of Asthma Trials and What They Involve
| Trial Type | Example | What It Tests | Typical Duration | Who It May Suit |
|---|
| Biologic therapy | ABRA (benralizumab), Wayfinder (tezepelumab) | Monoclonal antibodies targeting specific inflammatory pathways | 6 to 24 months | Adults with moderate-to-severe eosinophilic or uncontrolled asthma |
| Self-management intervention | IMP2ART | Strategies to help patients manage asthma in primary care settings | 12 to 36 months | Adults and children across all severity levels |
| Paediatric comparison | TREAT (mepolizumab vs omalizumab) | Head-to-head comparison of existing biologics in children | 12 to 24 months | Children with severe, difficult-to-control asthma |
| Oral small-molecule therapy | Rilzabrutinib phase 2 | BTK inhibitor for moderate-to-severe uncontrolled asthma | 3 to 12 months | Adults with persistent symptoms despite standard therapy |
Each trial has its own eligibility requirements. Some look for people with elevated blood eosinophil counts, others for those who have experienced recent exacerbations despite using high-dose inhalers. The screening process typically involves lung function tests, blood work, and a detailed review of your asthma history. You will not be asked to stop your current medications without a clear plan and close supervision.
How to Find and Join a Trial
The REACH register (Register for Asthma Research), run by the Asthma UK Centre for Applied Research, connects people affected by asthma with studies that match their profile. Signing up carries no obligation — it simply means researchers can contact you if a relevant trial opens. You can request details by emailing reachuk@ed.ac.uk.
The NIHR's "Be Part of Research" platform lists trials recruiting across England, Scotland, Wales, and Northern Ireland. You can filter by location, condition, and trial type, making it a practical starting point if you want to browse what is available near you. Many NHS trusts also have research teams embedded within respiratory departments — asking your consultant or asthma nurse during a routine appointment can open doors you might not find online. In London, organisations such as 4MCS run asthma trials focused on improving everyday symptom control, and similar groups operate in other regions.
A conversation with your GP or specialist is a sensible next step. They can advise on whether your current health status makes you a suitable candidate and whether any trial-related changes to your treatment regimen would be safe. Every trial in the UK undergoes ethical review by the Health Research Authority, and participants can withdraw at any point without affecting their standard NHS care.
What Participation Actually Looks Like
Most people imagine clinical trials as constant hospital visits and invasive procedures. In practice, many asthma trials are designed to fit around daily life. You might attend an initial screening visit, followed by regular check-ins every four to twelve weeks. Some trials incorporate remote monitoring — using a peak flow meter at home and logging symptoms via an app — reducing the need for travel. The IMP2ART trial, for instance, is embedded within GP practices, meaning participants engage with research through familiar settings rather than hospital clinics.
Sarah, a 34-year-old veterinary nurse from Leeds, joined a trial testing a new inhaler formulation after her asthma kept interrupting her work. "I was nervous about the commitment," she said, "but the research team was flexible with appointment times. I felt more closely monitored than I ever had through routine GP care." Her symptoms improved during the trial, and she has since encouraged colleagues with asthma to explore the REACH register.
The monitoring itself can be a benefit. Trial participants often receive more frequent lung function assessments and have direct access to specialist research nurses who can address concerns between visits. This heightened attention does not replace usual care — it sits alongside it, and many participants report feeling more informed about their condition as a result.
Understanding Risks and Safeguards
Every clinical trial carries unknowns. The treatment being tested may not work for you, and side effects — ranging from mild injection-site reactions to more significant immune responses — are possible. Trial protocols include detailed safety monitoring, and any concerning changes typically trigger a review by the research team and, if necessary, the study's independent safety committee.
The UK's regulatory framework requires that all clinical trials be approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and an independent ethics committee. Informed consent is a continuous process. You are not signing away your rights but agreeing to participate with full knowledge of what is involved, and you can ask questions at any stage. Travel expenses and, in some studies, compensation for time are often provided by trial sponsors, though arrangements vary. The research team will clarify all practical details before you consent.
A Quiet Word on Next Steps
If your current asthma management feels like a compromise rather than a solution, exploring clinical trials might be worth a conversation. The UK has a strong research infrastructure, and the distance between laboratory discoveries and patient-accessible treatments is narrowing — partly because more people are choosing to participate in studies.
The REACH register is a straightforward starting point. From there, speaking with your asthma nurse or specialist about what trials are recruiting locally can turn a vague interest into a concrete option. The research community needs people with all types of asthma — mild, moderate, severe, and everything in between — because the questions being asked are as varied as the people living with the condition.
研究の知恵